Mirae Asset Global Investments Co., Ltd. Gh Research PLC Transaction History

Mirae Asset Global Investments Co., Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	BUY	$5.26 - $11.04 $71,425 - $149,912	13,579 Added 14.64%	106,363 $616,000
Q3 2023 Oct 26, 2023	BUY	$9.8 - $14.15 $126,527 - $182,690	12,911 Added 16.16%	92,784 $932,000
Q2 2023 Aug 10, 2023	SELL	$7.88 - $12.74 $141,840 - $229,320	-18,000 Reduced 18.39%	79,873 $948,000
Q1 2023 May 04, 2023	SELL	$6.02 - $10.92 $47,467 - $86,104	-7,885 Reduced 7.46%	97,873 $782,000
Q4 2022 Feb 09, 2023	SELL	$9.2 - $13.5 $185,536 - $272,254	-20,167 Reduced 16.02%	105,758 $1.03 Million
Q3 2022 Nov 10, 2022	SELL	$10.15 - $16.15 $335,721 - $534,177	-33,076 Reduced 20.8%	125,925 $1.46 Million
Q2 2022 Jul 26, 2022	BUY	$8.99 - $19.87 $201,304 - $444,929	22,392 Added 16.39%	159,001 $1.59 Million
Q1 2022 May 10, 2022	BUY	$15.48 - $23.98 $12,523 - $19,399	809 Added 0.6%	136,609 $2.5 Million
Q4 2021 Feb 08, 2022	BUY	$14.1 - $27.9 $1.91 Million - $3.79 Million	135,800 New	135,800 $3.17 Million

23.5M

63.1K

1.9K

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $433M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.